{"id":383809,"date":"2023-12-11T09:39:04","date_gmt":"2023-12-11T08:39:04","guid":{"rendered":"https:\/\/medizinonline.com\/on-the-trail-with-sherlock-holmes-and-csi-mystery-cases-solved\/"},"modified":"2024-08-13T10:28:15","modified_gmt":"2024-08-13T08:28:15","slug":"on-the-trail-with-sherlock-holmes-and-csi-mystery-cases-solved","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/on-the-trail-with-sherlock-holmes-and-csi-mystery-cases-solved\/","title":{"rendered":"On the trail with Sherlock Holmes and CSI – Mystery cases solved"},"content":{"rendered":"\n

At the “somewhat different” AbbVie Symposium at this year’s Swiss Dermatology Congress (SGDV Congress) in Lausanne, experts did some excellent detective work: a missing person was found and the mysteriously altered behavior of a patient was also clarified.\nFind out here how Sherlock Holmes and the CSI agent were able to solve the cases at the symposium. <\/strong><\/p>\n\n\n\n

Psoriasis (PsO) and atopic dermatitis (AD) are incurable, inflammatory skin diseases that are caused by a dysregulation of the immune system and place a heavy physical and psychological burden on those affected [1, 2].\nWith the help of PD Dr. Florian Anzengruber alias “Sherlock Holmes” and Prof. Dr. med. nat. Christoph Schlapbach as a “CSI agent”, the “Director” Prof. Dr. med. Curdin Conrad was able to solve the disappearing symptoms of a PsO patient and the positive change of character of an AD patient.\nThe culprits: risankizumab and upadacitinib. <\/p>\n\n

Wanted: PsO symptoms<\/h2>\n\n

Pete Solomon Davies (P.so. D.) is missing – he was last seen with inflamed plaques on his skin and joint pain.\nIn order to find the missing man, Sherlock first diagnosed him with PsO.\nHe found two prescriptions for PsO treatment in his apartment: phototherapy and biologics.\nHe searched for more evidence and came across an analysis that showed that progression to psoriatic arthritis (PsA) was reduced in PsO patients treated with biologics (n = 234) compared to those treated with phototherapy (n = 230) [3].\nProgression to PsA was particularly reduced with IL-23 inhibitors (IL-23i) [4].\nPatient mortality was also reduced by systemic biologics treatment [5].\nAfter looking at the treatment history of P.so.\nD. (one administration of “Risa” every 12 weeks), Sherlock now knew that he had been treated with the IL-23i Risankizumab [6].\nRisankizumab had shown a sustained response in PsO patients over a period of 5.5 years in the LIMMitless-OLE study [7].\nSo the mystery was solved: P.so.\nD. was found, albeit without PsO plaques or joint complaints, but carefree in short summer pants. <\/p>\n\n

Mysterious behavioral change in AD patient<\/h2>\n\n

The mother of Abby Dean (A. D.) noticed some unusual changes in her adult daughter’s behavior: she looks different, is no longer tired, goes to work every day, is out and about a lot at weekends and often in short dresses.\nAre drugs involved here?\nTo get to the bottom of this, the CSI agent first looked at the patient’s diary, in which she complained of severe AD and asthma.\nHe also found empty packages of calcineurin inhibitors and steroids.\nFortunately, there was also a biopsy lying around – with an RNA analysis, the diagnosis of “atopic dermatitis” (AD) was made.\nThe agent remembered that JAK1 plays an important role in the pathogenesis of AD [8, 9].\nHe looked around the scene again and found an opened packet of 15mg upadacitinib with instructions for once-daily dosing [10].\nIn AD, the quality of life (QoL) of those affected is severely impaired, they are often unable to go to work and develop depression, anxiety or sleep disorders [11, 12].\nIn two studies, the agent then found that treatment with the JAK inhibitor upadacitinib can significantly reduce itching after just two days and significantly increase QoL in 75% of patients [13].\nSleep problems also decrease after 52 weeks, and up to 4 out of 10 of the treated patients show a clear skin appearance after 16 weeks of treatment (EASI 100) [14].\nThe case was thus solved: A. D. benefited greatly from the upadacitinib therapy and was thus able to return to an active life. <\/p>\n\n

Conclusion<\/h2>\n\n

Thanks to Sherlock Holmes and the CSI agent, the Director now knew that treatment with risankizumab for PsO and upadacitinib for AD had led to symptom freedom and positive personality changes respectively in our mysterious case studies.\nIn order to solve his cases in the future without the two detectives, he noted that early risankizumab treatment can reduce the progression of PsO and upadacitinib therapy can achieve a rapid improvement in skin appearance and QoL in AD patients [7, 13]. <\/p>\n\n

The cases presented are hypothetical case studies that were developed with the specialists.<\/p>\n\n

Abbreviations:<\/strong> AD = Atopic dermatitis; IL = Interleukin; JAK = Janus kinase; PsO = Psoriasis; TNF = Tumor necrosis factor; TSLP = Thymic stromal lymphopoietin; QoL = Quality of Life.<\/p>\n\n

<\/a>Brief technical information SKYRIZI\u00ae and RINVOQ\u00ae<\/a><\/p>\n\n

CH-SKZD-230090_11\/2023<\/p>\n\n

This article has been released in German.<\/p>\n\n

This article was produced with the financial support of AbbVie AG, Alte Steinhauserstrasse 14, Cham.<\/p>\n\n

Contribution online since 11.12.2023<\/p>\n\n

Literature<\/strong><\/p>\n\n

1 Gittler, J.K., et al, Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis.<\/em> J Allergy Clin Immunol, 2012. \n130<\/strong>(6): p. 1344-54. 2 Mahil, S.K., F. Capon, and J.N. Barker, Update on psoriasis immunopathogenesis and targeted immunotherapy.<\/em> Semin Immunopathol, 2016. \n38<\/strong>(1): p. 11-27. 3 Gisondi, P., et al, Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis.<\/em> Ann Rheum Dis, 2022. \n81<\/strong>(1): p. 68-73. 4 Singla, S., et al, Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.<\/em> The Lancet Rheumatology, 2023. \n5<\/strong>(4): p. e200-e207. 5 Langley, R.G., et al, Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis.<\/em> J Am Acad Dermatol, 2021. \n84<\/strong>(1): p. 60-69. 6. current expert information SKYRIZI\u00ae<\/sup> (risankizumab) at www.swissmedicinfo.ch.<\/em>7. Papp K et al. Long-term Safety and Efficacy of Risankizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: Interim Analysis of Results From the LIMMitless Open-label Extension Trial Beyond 5.5 Years of Follow-up. <\/em>Poster 43928. Presented at the 2023 American Academy of Dermatology Annual Meeting (AAD 2023), March 17-21, 2023, New Orleans, LA, United States.8 Furue, M., et al, Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies.<\/em>Allergol Int, 2017. \n66<\/strong>(3): p. 398-403. 9 Bao, L., H. Zhang, and L.S. Chan, The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis.<\/em> Jakstat, 2013. \n2<\/strong>(3): p. e24137. 10. current technical information RINVOQ\u00ae<\/sup> (upadacitinib) at www.swissmedicinfo.ch<\/a>11. Simpson, E.L., et al, Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults.<\/em> J Am Acad Dermatol, 2016. 74<\/strong>(3): p. 491-8.12 Whiteley, J., et al, The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey.<\/em> Curr Med Res Opin, 2016. 32<\/strong>(10): p. 1645-1651.13 Guttman-Yassky, E., et al, Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomized controlled phase 3 trials.<\/em> Lancet, 2021. 397<\/strong>(10290): p. 2151-2168.14 Simpson, E.L., et al, Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.<\/em> JAMA Dermatology, 2022. \n158<\/strong>(4): p. 404-413. <\/p>\n\n

The references can be requested by professionals at medinfo.ch@abbvie.com.<\/p>\n\n

\n","protected":false},"excerpt":{"rendered":"

At the “somewhat different” AbbVie Symposium at this year’s Swiss Dermatology Congress (SGDV Congress) in Lausanne, experts did some excellent detective work: a missing person was found and the mysteriously…<\/p>\n","protected":false},"author":14,"featured_media":383810,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"SGDV Congress 2023: Psoriasis and atopic dermatitis","footnotes":""},"category":[11548,11340,11323],"tags":[11648],"powerkit_post_featured":[],"class_list":["post-383809","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-en","category-dermatology-and-venereology","category-partner-content-en","tag-atopic-dermatitis-and-psoriasis-news","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-10 22:42:28","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":383806,"slug":"sur-la-piste-avec-sherlock-holmes-et-les-experts-mystery-cases-resolus","post_title":"Sur la piste avec Sherlock Holmes et Les Experts - Mystery cases r\u00e9solus","href":"https:\/\/medizinonline.com\/fr\/sur-la-piste-avec-sherlock-holmes-et-les-experts-mystery-cases-resolus\/"},"it_IT":{"locale":"it_IT","id":383803,"slug":"sulle-tracce-di-sherlock-holmes-e-csi-i-casi-di-mistero-risolti","post_title":"Sulle tracce di Sherlock Holmes e CSI - I casi di mistero risolti","href":"https:\/\/medizinonline.com\/it\/sulle-tracce-di-sherlock-holmes-e-csi-i-casi-di-mistero-risolti\/"},"pt_PT":{"locale":"pt_PT","id":383800,"slug":"na-pista-com-sherlock-holmes-e-csi-casos-de-misterio-resolvidos","post_title":"Na pista com Sherlock Holmes e CSI - Casos de mist\u00e9rio resolvidos","href":"https:\/\/medizinonline.com\/pt-pt\/na-pista-com-sherlock-holmes-e-csi-casos-de-misterio-resolvidos\/"},"es_ES":{"locale":"es_ES","id":383797,"slug":"tras-la-pista-de-sherlock-holmes-y-csi-casos-misteriosos-resueltos","post_title":"Tras la pista de Sherlock Holmes y CSI - Casos misteriosos resueltos","href":"https:\/\/medizinonline.com\/es\/tras-la-pista-de-sherlock-holmes-y-csi-casos-misteriosos-resueltos\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/383809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=383809"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/383809\/revisions"}],"predecessor-version":[{"id":383811,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/383809\/revisions\/383811"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/383810"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=383809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=383809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=383809"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=383809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}